论文部分内容阅读
作为胰腺癌的血清学诊断方法,受到注目的肿瘤标志有胰癌胎儿抗原(POA)。Banwo 等于1974年首次报道,继之欧美、日本亦有许多报道。但由于各报道者对POA 的取材及制备过程不同,所以其生化学、免疫学的特性亦有差异。有关POA 的本质尚有许多不明之处,且临床上具有大规模而又严格地研究报道很少,故其临床价值尚未明确。作者按Gelder 等方法采用胰腺癌患者血
As a serodiagnosis method for pancreatic cancer, a tumor marker attracting attention is pancreatic cancer fetal antigen (POA). Banwo was the first report in 1974, followed by many reports in Europe, America and Japan. However, due to the different sources and preparation processes of POA in each reporter, their biochemical and immunological characteristics are also different. There are still many unknowns about the nature of POA, and there are few large-scale and rigorous research reports in clinical practice, so its clinical value is not yet clear. The authors used pancreatic cancer patients according to Gelder et al.